



Pharmacy Formulary Updates for June 2020

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in June 2020:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Viscosupplements-Euflexxa	MB;PA
Viscosupplements- Durolane, Genvisc 850, Trivisc, Visco-3, Hyalgan, Gelsyn-3, Supartz FX, Hymovis, Orthovisc, Synvisc, Synvisc-One, Gel-One, Monovisc	MB;NC
Vumerity (diroximel fumarate)	NC, SP
Sarclisa (isatuximab-irfc)	MB
Scenesse (afamelanotide)	MB, PA
Tepezza (teprotumumab-trbw)	MB, PA
Palforzia (peanut powder-dnfp)	Tier 3, PA
Hyperrab (rabies immune globulin) 300 UNT/ML injection	MB
Romidepsin IV solution	MB
Arazlo (tazarotene) 0.045% lotion	NC
Ajovy (fremanezumab-vfrm) auto-injector	Tier 2, PA, QL (3 pens/90 days)
Glucagon EMR (glucagon emergency kit)	Tier 2
Trijardy XR (empagliflozin-linagliptin-metformin)	NC
OSMOLEX ER TAB	NC
NYMALIZE SOL (NIMODIPINE ORAL SOLN 6 MG/ML)	T3
SSKI Solution	T3
Truvada	T2, (May be covered at no copayment for HIV PrEP)
Descovy	T2, PA, (May be covered at no copayment for HIV PrEP)

Key:

MB: Medical Benefit	QL: Quantity Limitation
NC: Not covered	SP: Specialty Pharmacy - provided through CVS/specialty
NTM: New-to-market	ST: Step Therapy
PA: Prior Authorization	